We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase
Read MoreHide Full Article
Dr. Reddy's Laboratories Limited (RDY - Free Report) reported first-quarter fiscal 2023 earnings of 90 cents per American Depositary Share compared with 43 cents (excluding impairment charges) reported in the year-ago quarter.
In first-quarter fiscal 2023, revenues grew 6% year over year to $660 million.
Shares of the company have decreased 20% in the year compared with the industry’s decline of 23.7%.
Image Source: Zacks Investment Research
Quarter in Detail
Dr. Reddy’s reports revenues under three segments — Global Generics; Pharmaceutical Services & Active Ingredients (“PSAI”); and Proprietary Products and Others.
Global Generics revenues were INR 44.3 billion, up 8% year over year, in the fiscal first quarter. Growth was led by new product launches across businesses and the divestment of a few non-core brands in India.
The company launched seven products in North America, including Ketorolac, OTC Nicotine Lozenges Original, Methylprednisolone Sodium Succinate, Pemetrexed Injection, Posaconazole Tabs and Sorafenib in the US, and Pemetrexed injection in Canada
As of Jun 30, cumulatively, 86 generic filings were pending approval from the FDA (83 abbreviated New Drug Applications [ANDAs] and three new drug applications). Of these 86 ANDAs, 44 are Para IVs and 24 have first-to-file status.
PSAI revenues were INR 7.1 billion, down 6% from the year-ago quarter, primarily due to a higher base that took place in first-quarter fiscal 2022 with covid product sales.
Revenues in the other segment came in at INR 740 million, up 37% year over year.
Research and development expenses were down 5% year over year to $55 million. The company is focused on building a global pipeline of new products across its markets.
Selling, general and administrative expenses were $196 million, up 3% year over year, primarily owing to investments in the marketing of some key brands and investments in digitalization and annual increment.
Our Take
In first-quarter fiscal 2023, Dr. Reddy’s top line and bottom line both registered year-over-year growth.
However, the company continues to face price erosion in the North American generics market, which will adversely impact sales.
Beam Therapeutics’ loss per share estimates narrowed 0.7% for 2022 and 0.8% for 2023 in the past 60 days.
Earnings of Beam Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the remaining occasion. BEAM delivered an earnings surprise of 1.80%, on average.
Atara Biotherapeutics’ loss per share estimates narrowed 0.6% for 2022 and 13.3% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. ATRA delivered an earnings surprise of -12.51%, on average.
Precision BioSciences’ loss per share estimates narrowed 5.8% for 2022 and 16.2% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase
Dr. Reddy's Laboratories Limited (RDY - Free Report) reported first-quarter fiscal 2023 earnings of 90 cents per American Depositary Share compared with 43 cents (excluding impairment charges) reported in the year-ago quarter.
In first-quarter fiscal 2023, revenues grew 6% year over year to $660 million.
Shares of the company have decreased 20% in the year compared with the industry’s decline of 23.7%.
Image Source: Zacks Investment Research
Quarter in Detail
Dr. Reddy’s reports revenues under three segments — Global Generics; Pharmaceutical Services & Active Ingredients (“PSAI”); and Proprietary Products and Others.
Global Generics revenues were INR 44.3 billion, up 8% year over year, in the fiscal first quarter. Growth was led by new product launches across businesses and the divestment of a few non-core brands in India.
The company launched seven products in North America, including Ketorolac, OTC Nicotine Lozenges Original, Methylprednisolone Sodium Succinate, Pemetrexed Injection, Posaconazole Tabs and Sorafenib in the US, and Pemetrexed injection in Canada
As of Jun 30, cumulatively, 86 generic filings were pending approval from the FDA (83 abbreviated New Drug Applications [ANDAs] and three new drug applications). Of these 86 ANDAs, 44 are Para IVs and 24 have first-to-file status.
PSAI revenues were INR 7.1 billion, down 6% from the year-ago quarter, primarily due to a higher base that took place in first-quarter fiscal 2022 with covid product sales.
Revenues in the other segment came in at INR 740 million, up 37% year over year.
Research and development expenses were down 5% year over year to $55 million. The company is focused on building a global pipeline of new products across its markets.
Selling, general and administrative expenses were $196 million, up 3% year over year, primarily owing to investments in the marketing of some key brands and investments in digitalization and annual increment.
Our Take
In first-quarter fiscal 2023, Dr. Reddy’s top line and bottom line both registered year-over-year growth.
However, the company continues to face price erosion in the North American generics market, which will adversely impact sales.
Zacks Rank & Stocks to Consider
Dr. Reddy's currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Beam Therapeutics Inc. (BEAM - Free Report) , Atara Biotherapeutics, Inc. (ATRA - Free Report) and Precision BioSciences, Inc. (DTIL - Free Report) , all sporting a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Beam Therapeutics’ loss per share estimates narrowed 0.7% for 2022 and 0.8% for 2023 in the past 60 days.
Earnings of Beam Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the remaining occasion. BEAM delivered an earnings surprise of 1.80%, on average.
Atara Biotherapeutics’ loss per share estimates narrowed 0.6% for 2022 and 13.3% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. ATRA delivered an earnings surprise of -12.51%, on average.
Precision BioSciences’ loss per share estimates narrowed 5.8% for 2022 and 16.2% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.